Aaron Wealth Advisors LLC acquired a new position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Rating) in the first quarter, according to its latest 13F filing with the Securities and Exchange Commission. The institutional investor acquired 5,662 shares of the company, valued at approximately $603,000.
A number of other major investors have also recently changed their stakes in the company. Red Cedar Capital LLC increased its stake in Teva Pharmaceutical Industries by 0.7% in the fourth quarter. Red Cedar Capital LLC now owns 185,920 shares of the company valued at $1,489,000 after purchasing an additional 1,250 shares in the last quarter. National Bank of Canada FI increased its stake in Teva Pharmaceutical Industries by 1.3% in the 1st quarter. National Bank of Canada FI now owns 109,526 shares of the company valued at $1,025,000 after purchasing an additional 1,392 shares in the last quarter. Morningstar Investment Services LLC increased its stake in Teva Pharmaceutical Industries by 5.5% in Q1. Morningstar Investment Services LLC now owns 26,631 shares of the company valued at $245,000 after buying 1,395 additional shares in the last quarter. Ensign Peak Advisors Inc increased its stake in Teva Pharmaceutical Industries by 3.4% in the fourth quarter. Ensign Peak Advisors Inc now owns 45,850 shares of the company valued at $367,000 after purchasing an additional 1,500 shares in the last quarter. Finally, Transcend Capital Advisors LLC increased its stake in Teva Pharmaceutical Industries by 17.4% in the 1st quarter. Transcend Capital Advisors LLC now owns 12,850 shares of the company valued at $121,000 after purchasing an additional 1,900 shares in the last quarter. 45.79% of the shares are currently held by institutional investors and hedge funds.
Analysts set new price targets
Several equity research analysts have recently released reports on TEVA shares. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a Friday, June 17 research note. Goldman Sachs Group raised its price target on Teva Pharmaceutical Industries shares from $9.00 to $10.00 and gave the company a “neutral” rating in a Tuesday, Aug. 2 report. UBS Group assumed coverage of Teva Pharmaceutical Industries shares in a Monday, June 13 report. They issued a “neutral” rating and a $10.00 price target on the stock. Bank of America downgraded shares of Teva Pharmaceutical Industries from a “neutral” to a “buy” rating and raised its price target for the company from $10.00 to $13.00 in a Friday report. 5 August. Finally, Piper Sandler cut shares of Teva Pharmaceutical Industries from a “neutral” rating to an “underweight” rating and lowered her price target for the company from $11.00 to $7.00 in a report Wednesday, May 4. One analyst rated the stock with a sell rating, four assigned a hold rating and four assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $10.67.
Teva Pharmaceutical Industries stock up 0.3%
Shares of TEVA opened at $10.37 on Friday. Teva Pharmaceutical Industries Limited has a 12-month low of $6.78 and a 12-month high of $11.34. The company’s 50-day moving average is $8.53 and its 200-day moving average is $8.58. The stock has a market capitalization of $11.44 billion, a PE ratio of -10.92, a P/E/G ratio of 4.03 and a beta of 1.31. The company has a current ratio of 1.11, a quick ratio of 0.74 and a debt ratio of 2.07.
Insider Trading at Teva Pharmaceutical Industries
In other news, Vice Chairman David Matthew Stark sold 58,163 shares of the company in a trade that took place on Thursday, July 28. The shares were sold at an average price of $9.04, for a total transaction of $525,793.52. Following the transaction, the vice president now directly owns 2,974 shares of the company, valued at $26,884.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, accessible via the SEC’s website. Insiders own 0.82% of the shares of the company.
About Teva Pharmaceutical Industries
(Get a rating)
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets and distributes generic drugs, specialty drugs and biopharmaceuticals in North America, Europe and internationally. The company offers sterile products, hormones, high potency drugs and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments and creams.
Get news and reviews for Teva Pharmaceutical Industries Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com’s FREE daily newsletter.